Figure 1.

Division of Lung Diseases (DLD) portfolio for fiscal year (FY) 2017 and FY 2018. The pie chart (A) shows the percentage of grant funding allocated for common and rare diseases research. The bar chart (B) lists the rare lung diseases that make up ≥ 2% of the DLD rare disease portfolio (in dollars). CF = cystic fibrosis; IPF = idiopathic pulmonary fibrosis; LAM = lymphangioleiomyomatosis; Other = rare diseases or conditions that make up < 2% of the DLD rare lung disease portfolio and are listed here in alphabetical order: acute myeloid leukemia, alpha-1 antitrypsin deficiency, alveolar capillary dysplasia, amyotrophic lateral sclerosis, aspergillosis, bronchiolitis obliterans syndrome, congenital diaphragmatic hernia, chronic beryllium disease, chronic thromboembolic pulmonary hypertension, Duchenne muscular dystrophy, Hermansky-Pudlak syndrome, Hutchinson-Gilford progeria syndrome, Löfgren syndrome, lung transplantation, lysosomal storage disorder, non-TB mycobacterial lung disease, Pallister-Hall syndrome, pediatric ARDS, pleuropulmonary blastoma, pulmonary alveolar proteinosis, pulmonary ciliary dyskinesia, respiratory distress syndrome, Rett syndrome, rheumatoid arthritis-associated interstitial lung disease, sarcoidosis, sickle cell disease, sudden infant death syndrome, tetralogy of Fallot, thalassemia, tracheoesophageal fistula, X-linked myotubular myopathy; PAH = pulmonary arterial hypertension.